Chang Gon Kim

Yonsei University — South Korea

Medicine · Health Sciences

18h-index890citations187works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(108), Head and Neck Cancer Studies(84), Colorectal and Anal Carcinomas(83), Lung Cancer Treatments and Mutations(34), Lung Cancer Diagnosis and Treatment(17)

Publications187 total

Computed tomography-based unsupervised clustering identifies clusters associated with progression free survival in clear cell renal cell carcinoma
Cancer Imaging·2025Open Access
Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial
EClinicalMedicine·2025Open Access
HER2 Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-institutional Analysis
Clinical Cancer Research·2025
549 Phase 2 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with head and neck squamous cell carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study
Lung Cancer·2025
588 Selective inhibition of Diacylglycerol kinase zeta exhibits increased T cell activation and anti-tumor immunity, demonstrating pharmacodynamic proof of mechanism in the FIH trial of BAY2965501
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract A093: VRN110755 Shows Promise with Improved Efficacy in EGFR mutation NSCLC: Highlighting CNS activity, Potency Against Resistant EGFR Mutations, and a Favorable Safety Profile
Molecular Cancer Therapeutics·2025
A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma
Oral Oncology·2025· 1 cited
4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy
Cell Reports Medicine·2025· 2 citedOpen Access
Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum
Cancers·2025Open Access
Supplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S1 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S20 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S7 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S5 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S18 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figure S17 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S2 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Table S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
2025Open Access
page 1 of 10Next →

Frequent Co-authors

Min Hee Hong(19), Byoung Chul Cho(16), Sun Min Lim(14), Hye Ryun Kim(12), Kyoung‐Ho Pyo(10), Yoon Woo Koh(9), Mi Ran Yun(7), Gamin Kim(7), Kyung Hwan Kim(7), Beung‐Chul Ahn(7), Minkyu Jung(7), Sun Young Rha(7), Jae Hwan Kim(7), Hyunki Kim(6), Chun‐Bong Synn(6), Hyo Song Kim(6), Sun Och Yoon(6), Young Seob Kim(6), Nam Suk Sim(6), Dahee Kim(6)